Experts have made a raft of recommendations about how early clinical studies of new drugs should be designed, to improve their safety for the people taking part.

An interim report from an expert scientific group chaired by Gordon Duff, professor of molecular medicine at Sheffield University and chairman of the government's Commission on Human Medicines, says that new high risk agents in phase I studies—the first time drugs are tested in humans—should be given to one …